Data Insights

MRG-002 by Shanghai Miracogen for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Gastroesophageal (GE) Junction Carcinomas

Data Insights

MRG-002 by Shanghai Miracogen for Metastatic Breast Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Metastatic Breast Cancer

Data Insights

MRG-002 by Shanghai Miracogen for Gastric Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Gastric Cancer

Data Insights

MRG-003 by Shanghai Miracogen for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

MRG-003 is under clinical development by Shanghai Miracogen and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-003 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

MRG-003 by Shanghai Miracogen for Non-Small Cell Lung Cancer: Likelihood of Approval

MRG-003 is under clinical development by Shanghai Miracogen and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-003 in Non-Small Cell Lung Cancer

Data Insights

MRG-003 by Shanghai Miracogen for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

MRG-003 is under clinical development by Shanghai Miracogen and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-003 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

MRG-002 by Shanghai Miracogen for Bladder Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Bladder Cancer

Data Insights

MRG-002 by Shanghai Miracogen for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

MRG-002 by Shanghai Miracogen for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

MRG-002 by Shanghai Miracogen for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Data Insights

MRG-002 by Shanghai Miracogen for Bladder Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Bladder Cancer. According to GlobalData, Phase...

Data Insights

MRG-002 by Shanghai Miracogen for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Metastatic Transitional (Urothelial) Tract Cancer. According...

Data Insights

MRG-002 by Shanghai Miracogen for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Human Epidermal Growth Factor Receptor 2...

Data Insights

MRG-004A by Shanghai Miracogen for Cervical Cancer: Likelihood of Approval

MRG-004A is under clinical development by Shanghai Miracogen and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-004A in Cervical Cancer

Data Insights

MRG-004A by Shanghai Miracogen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

MRG-004A is under clinical development by Shanghai Miracogen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-004A in Triple-Negative Breast Cancer (TNBC)

Data Insights

MRG-004A by Shanghai Miracogen for Pancreatic Cancer: Likelihood of Approval

MRG-004A is under clinical development by Shanghai Miracogen and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MRG-004A in Pancreatic Cancer